August 2012

New data show that cancer-related fatigue is reported by only "a small minority" of women >6 months after completing adjuvant therapy for breast cancer.

Partial nephrectomy is associated with better overall survival than radical nephrectomy in older patients with early-stage kidney cancer.

The Trials in Progress Poster Session at the ASCO Annual Meeting, now in its third year, is intended to stimulate discussion in the oncology community about ongoing clinical trials and to promote collaboration.

Siteman patients have access to more than 250 therapeutic clinical trials, and Siteman-affiliated scientists and physicians hold more than $165 million in annual cancer research and related training grants.

Anemia is common and associated with functional disability in patients with cancer aged ≥65 years, according to the results of a study presented at ASCO 2012.

Patients with cancer who have lower incomes are less likely to participate in clinical trials, according to a large national survey.

The oral hedgehog pathway inhibitor vismodegib is effective for both the prevention and treatment of basal-cell carcinoma in patients with the rare disorder known as basal-cell nevus syndrome.

Lenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patients with multiple myeloma.

Two medications that are not recommended in guidelines for the standard treatment of cancer-related febrile neutropenia are commonly used- particularly outside of high-volume medical settings- yet are not effective.

Colonoscopy is effective for the prevention of colorectal cancer deaths, according to the results of a large, population-based, case-control study.

A new paradigm that relies on identifying networks or clusters of single nucleotide polymorphisms can accurately predict which patients will develop treatment-related mucositis and other side effects.

A "substantial minority" of radiation oncologists report that surgeons fail to include them in the breast cancer treatment decision-making process before definitive surgery.

To be transformative, we need to think outside the box, and maybe it will take a computer visionary and a fairytale to guide us.

Research is needed to justify the dollar savings achieved by a supportive care program, but it is not clear what should be measured and how studies should be designed to demonstrate this.